In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers.
One of the most important factors in choosing a treatment strategy for cancer is characterization of biomarkers in cancer cells. Particularly, recent advances in Monoclonal Antibodies (MAB) as primary-specific drugs targeting tumor receptors show that their efficacy depends strongly on characterizat...
Main Authors: | Yasaman Ardeshirpour, Victor Chernomordik, Rafal Zielinski, Jacek Capala, Gary Griffiths, Olga Vasalatiy, Aleksandr V Smirnov, Jay R Knutson, Ilya Lyakhov, Samuel Achilefu, Amir Gandjbakhche, Moinuddin Hassan |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3285647?pdf=render |
Similar Items
-
In Vivo Method to Monitor Changes in HER2 Expression Using Near-Infrared Fluorescence Imaging
by: Moinuddin Hassan, et al.
Published: (2012-05-01) -
Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors
by: Yasaman Ardeshirpour, et al.
Published: (2018-04-01) -
Fluorescence Lifetime Imaging System for in Vivo Studies
by: Moinuddin Hassan, et al.
Published: (2007-07-01) -
Quantitative Analysis of HER2 Receptor Expression In Vivo by Near-Infrared Optical Imaging
by: Victor Chernomordik, et al.
Published: (2010-07-01) -
Multiscale BerEp4 Molecular Imaging of Microtumor Phantoms: Toward Theranostics for Basal Cell Carcinoma
by: Bahar Dasgeb, et al.
Published: (2014-08-01)